Supported by grants from the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital (New York, NY, USA), The Macula Foundation, Inc., (New York, NY, USA), the National Eye Institute (EY06109; Bethesda, MD, USA) Research to Prevent Blindness, Inc. (New York, NY, USA), EyeSight Foundation of Alabama (Birmingham, AL, USA), and The RANZCO Eye Foundation (New South Wales, Australia).
Disclosure: C. Balaratnasingam, None; L.A. Yannuzzi, Genentech (R); C.A. Curcio, Genentech (C, R), Novartis (C, R), Merck (C, R), Janssen Cell Therapy (C, R), Regeneron (C, R), Ora (C, R); W.H. Morgan, None; G. Querques, Alimera Sciences, Inc. (C, S), Allergan, Inc. (C, S), Bayer Schering Pharma (C, S), Novartis Pharmaceuticals Corporation, (C, S), Bausch&Lomb (C), Ophthotech (C); V. Capuano, None; E. Souied, Allergan (C, R, S), Bayer (C, R, S), Novartis (C, R, S), Bausch&Lomb (S); J. Jung, None; K.B. Freund, Genentech (C, R), Bayer HealthCare (C, R), Optovue (C, R), ThromboGenics (C, R), Ohr Pharmaceutical (C, R), Heidelberg Engineering (C R)